Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO

Use of Prone Position Ventilation (PPV) in Danish Patients With COVID-19 Induced Severe Adult Respiratory Distress Syndrome (ARDS) Treated With Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05693051

Enrollment

Registered

2023-01-20

Start date

2020-10-01

Completion date

2022-11-01

Last updated

2023-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Human, Extracorporeal Membrane Oxygenation, COVID-19 Acute Respiratory Distress Syndrome, Prone Position, Adverse Event

Keywords

ARDS, VV-ECMO, Prone position ventilation, Adverse Events

Brief summary

Prone position ventilation was used 220 times in 44 out of 68 patients with severe COVID-19 induced ARDS treated with VV-ECMO. PPV treated patients did not benefit from PPV and the incidence of PPV related adverse events was high

Detailed description

Purpose: To describe the use and effects of prone position ventilation (PPV) in patients with COVID-19 induced Adult Respiratory Distress Syndrome (ARDS), treated with Veno-Venous Extracorporeal membrane oxygenation (VV-ECMO). Methods: Nationwide retrospective analysis of all COVID-19 patients in Denmark from March 2020 - December 2021with severe ARDS and need of VV-ECMO treatment. Data on the number of patients treated with PPV, number of PPV-events, timing, the time spent in prone position, physiological response types, adverse events and outcomes are reported.

Interventions

OTHERProne position ventilation

Turning the patient prone for 16 hours

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

patients with COVID-19 induced severe ARDS accepted for and treated with VV-ECMO in Denmark \-

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
90 day mortality	90 days	all cause mortality 90 days after ECMO start

Secondary

Measure	Time frame	Description
Time-to-wean	From start of ECMO treatment to succesful weaning from ECMO	Time from ECMO start to succesful weaning from ECMO
Recruitment Response to prone position ventilation	from prone position start to prone position end	lung recruitment
Oxygenation Response to prone position ventilation	from prone position start to prone position end	Oxygenation

Other

Measure	Time frame	Description
Adverse Events	From ECMO start to ECMO end (all causes)	Number and nature of adverse events related to prone position ventilation

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026